Year: 2024
Type: article
Study design: Case Report
Abstract: Clozapine is widely recognized as a last-resort treatment for resistant schizophrenia, due to its efficacy in reducing persistent symptoms and lowering the risk of suicidal behavior. However, its use is limited by severe side effects, including hematological complications such as agranulocytosis. A less documented but significant complication is clozapine-induced polycythemia. This case study explores the development of polycythemia in a patient undergoing clozapine treatment for refractory schizophrenia. Despite the reduction of clozapine doses, polycythemia persisted, necessitating continued treatment due to the lack of alternative therapeutic options. The patient’s hematological abnormalities were managed through regular phlebotomies, and close collaboration between psychiatric and hematological services. This case emphasizes the importance of rigorous hematological monitoring in patients on clozapine and calls for further research into its effects on the hematopoietic system, particularly concerning polycythemia. The mechanisms underlying this association are not well understood but may involve immune-mediated responses, bone marrow alterations, and metabolic changes, necessitating multidisciplinary management for optimal patient care.
Source: SAS Journal of Medicine
Institution: Centre Hospitalier Universitaire de Rabat-Salé
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4402991213